{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"65","value":"47.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The time from onset of any visual acuity event (change from baseline logMAR score \\>= 0.3 in either eye) until the event is resolved (change from baseline logMAR score \\< 0.3 in both eyes) was used to calculate the duration of first occurrence.","dispersionType":"Full Range","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"MEDIAN","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 178 weeks","title":"Part 2 - Duration of First Occurrence of Worsening in BCVA Score","type":"SECONDARY","unitOfMeasure":"Days"}